Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols

ABSTRACT: Primary objectives: To evaluate the long-term safety and tolerability of napabucasin through the evaluation of AEs, clinically significant physical examination findings, and clinically relevant laboratory results. Primary endpoints: 1. Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE versión 4.0), seriousness, and relationship to study therapy.2. Laboratory abnormalities as characterized by type, frequency, and severity (as graded by NCIC version 4.0).3. Vital signs.4. Physical examination.5. ECG.

DISEASE(S): Metastatic Pancreatic Adenocarcinoma And Metastatic Colorectal Cancer.

PROVIDER: 2555772 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I/II study of immuntoxin for treatment of metastatic abdominaldisease in patient with colorectal cancer.

Project description:Primary objectives: To assess safety and toxicity (Dose Limiting Toxicity) after intraperitoneal administration of MOC31PE. Primary endpoints: Frequency and severity of adverse events and serious adverse events.The NCI Common Terminology Criteria for Adverse Events Version 4.0(CTCAE) will be used.Changes in laboratory values, vital signs and ECOG performance statuswill also be assessed.

| 2531813 | ecrin-mdr-crc

Nk-1 receptor antagonist, 5-ht3 receptor antagonist and dexamethasone antiemetic regimen to prevent nausea and vomiting induced by chemotherapy drugs with high emetic risk for several days

Project description:Interventions: single arm:Nk-1 receptor antagonist, 5-ht3 receptor antagonist and dexamethasone antiemetic regimen Primary outcome(s): According to the international evaluation system for adverse reactions to chemotherapy drugs (CTCAE) version 4.03. Nausea is defined as a condition characterized by nausea and/or an urgent need for vomiting.;Complete remission rate (CR): number of CINV complete remission patients/number of chemotherapy patients x100%; CINV complete remission was defined as (CTCAE) version 4.03, nausea and vomiting grade 0 (no nausea and vomiting).;Adverse reactions: adverse events and laboratory tests were graded according to NCI CTC AE 4.0, and special attention should be paid to early withdrawal from the study as well as vital signs (such as blood pressure, body temperature, etc.), intestinal obstruction, intractable hiccups, uncontrollable headaches, etc. Study Design: Single arm

| 2685822 | ecrin-mdr-crc

Association of childhood chronic physical aggression with a DNA methylation signature in adult human T cells

Project description:Chronic physical aggression (CPA) is characterized by frequent use of physical aggression from early childhood to adolescence. Observed in approximately 5% of males, it is associated with early childhood adverse environments. DNA methylation, a covalent modification of DNA, regulates genome function and has been associated with early childhood adverse environments. We analyzed T cell DNA genome-wide promoter methylation profiles from two groups of adult males assessed annually for frequency of physical aggression between 6 and 15 years of age: a group with CPA and a control group. Whole genome methylation analysis was performed using MeDIP followed by hybridization to microarrays. We mapped the promoter regions of 20 000 genes and 400 microRNAs. The subjects were recruited from participants in two longitudinal studies of child development9,47. We recruited two groups of Caucasian males who were born in families with a low socioeconomic status and were living at the time of the present study within 200km from our laboratory. The first group had a history of high physical aggression from age 6 to 15 years (chronic physical aggression group, CPA). The second group was recruited from the same longitudinal studies but included only those who did not have a history of high physical aggression from age 6 to 15 (Control group). A total of 65 eligible subjects agreed to participate (8 CPA and 57 controls). Using custom-designed microarrays with 244K probes tiling the promoter regions of 20000 genes and 400 microRNAs, we obtained DNA methylation profiles by meDIP-chip. Each profile was generated in triplicate.

2013-09-30 | E-GEOD-50674 | biostudies-arrayexpress

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients

Project description:1. Study Objectives 1) Primary Objective: Progression-free survival 2) Secondary Objectives: 1. overall survival 2. response rate 3. incidence, nature and severity of all adverse events 4. lipid lowering effect of simvastatin 5. exploratory biomarker analysis : angiopoietin 2, BiP (Binding protein), Hsp (Heat shck protein) 90α 2. Study hypothesis In our recent in vitro study, addition of simvastatin to bevacizumab reduced proliferation, migration, invasion and tumor formation of endothelial cell. Moreover, colorectal cancer cell media which was treated with simvastatin combined with bevacizumab inhibited endothelial cell invasion and it was associated with decreased mediator of angiogenesis, such as angiopoietin 2, BiP and HSP 90α.. Treatment with bevacizumab and simvastatin more reduced the growth of xenograft tumors compared with bevacizumab alone. 3. Assessments 1) Safety : physical examination, vital signs, body weight, ECOG (Eastern Cooperative Oncology Group) performance status, clinical laboratory evaluation (chemistry, blood cell count) and any AE (adverse effect) graded by using CTCAE (Common Toxicity Criteria for Adverse Effects ) v 4.0 2) Efficacy : progression-free survival and overall survival will be collected. Response rate according to RECIST (Response Evaluation Criteria in Solid Tumors) 1,1 guideline will also be evaluated 3) PFS (Progression free survival): time from randomization to tumor progression or death 4) OS (Overall survival) : time from randomization to death or last follow-up 5) Biomarker analysis; The correlation between blood level, protein expression of angiopoietin 2, BiP, Hsp90α and clinical response will be explored.

| 2158040 | ecrin-mdr-crc

Transcription profiling of human placenta from women presenting at term with villitis of unknown etiology

Project description:Placental villous tissue from women at term presenting various degrees of villitis of unknown etiology were analysed using Affymetrix microarrays. The severity of inflammation was graded using four levels: 0(no inflammation), 1(mild inflammation - multifocal low grade villitis), 2(moderate inflammation - patchy high grade villitis), and 3(severe inflammation - diffuse high grade villitis).

2009-01-04 | E-TABM-577 | biostudies-arrayexpress

Proteomics of Human Skeletal Muscle

Project description:The skeletal muscle proteomics study of vastus lateralis muscle biopsies which were collected from participants from the Genetic and Epigenetic Study of Aging and Laboratory Testing (GESTALT). The participants were free of major diseases, except for controlled hypertension or a history of cancer that had been clinically silent for at least 10 years, were not chronically medicated (except one on antihypertensive medication), had no physical or cognitive impairments, had a BMI less than 30 kg/m2, and were not professional athletes.

2019-11-14 | PXD011967 | Pride

Verification of Molecular Subtyping of Bladder Cancer in the GUSTO Clinical Trial

Project description:The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle-invasive bladder cancer (MIBC). Before commencing the GUSTO trial, we needed to determine the reliability of a commercial subtyping platform (Decipher Bladder; Veracyte) when performed in an external trial laboratory as this has not been done previously. Here we report our pre-trial verification of the TCGA molecular subtyping model using gene expression profiling. Formalin fixed paraffin embedded tissue blocks of MIBC were used for gene expression subtyping by gene expression microarrays. Intra- and inter-laboratory technical reproducibility, together with quality control of laboratory and bioinformatics processes were assessed. Eighteen samples underwent analysis. RNA of sufficient quality and quantity was successfully extracted from all samples. All subtypes were represented in the cohort. Each sample was subtyped twice in our laboratory and once in a separate reference laboratory. No clinically significant discordance in subtype occurred between intra- or inter-laboratory replicates. Examination of sample histopathology showed variability of morphological appearances within and between subtypes. Overall, these results show that molecular subtyping by gene expression profiling is reproducible, robust, and suitable for use in the GUSTO clinical trial.

2024-01-18 | GSE253531 | GEO

DNA Methylation Signature of Childhood Chronic Physical Aggression in T Cells of Both Men and Women (Agilent)

Project description:High frequency of physical aggression is the central feature of severe conduct disorder and is associated with a wide range of social, mental and physical health problems. We have previously tested the hypothesis that differential DNA methylation signatures in peripheral T cells are associated with a chronic aggression trajectory in males. Despite the fact that sex differences appear to play a pivotal role in determining the development, magnitude and frequency of aggression, most of previous studies focused on males, so little is known about female chronic physical aggression. We therefore tested here whether or not there is a signature of physical aggression in female DNA methylation and, if there is, how it relates to the signature observed in males. Genome-wide promoter methylation profiles of T cell DNA from adult females on a Chronic Physical Aggression (CPA, n=5) trajectory during childhood and adolescence were compared to those on normative physical aggression trajectories (NPA, n=14). Two technical replicates were generated for each individual.

2013-12-11 | E-GEOD-53192 | biostudies-arrayexpress

Blood genome expression Profiles in Infants with Congenital Cytomegalovirus Infection: Is the asymptomatic infant truly asymptomatic?

Project description:Background: Congenital cytomegalovirus (cCMV) infection represents the most frequent non-genetic cause of sensorineural hearing loss (SNHL). The disease spectrum varies from clinically apparent (“symptomatic”) to clinically inapparent (“asymptomatic”). Analysis of host genome expression profiles has provided new insights into disease pathogenesis and assessment of clinical severity. Its value as a biomarker in infants with cCMV has not been explored. Methods: Infants with cCMV infection, both symptomatic and asymptomatic, were enrolled at a median age of 17 days of age and followed up for 3 years to assess the development of SNHL. Healthy age matched controls were also enrolled as a reference. Blood samples were obtained at enrollment and follow-up to assess host responses by RNA transcriptional profiling. Symptomatic CMV was defined as the presence of any clinical, laboratory, ophthalmologic, audiologic or neuroimaging abnormalities.

2020-05-26 | GSE108211 | GEO